ID   OP-9S
AC   CVCL_HC57
DR   Wikidata; Q54936438
RX   Patent=US9121008;
RX   PubMed=15650053;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10785.
CC   Characteristics: Slow-growing derivative of OP9.
CC   Characteristics: Does not produce Csf1 (M-CSF) due to a mutation in the gene.
CC   Doubling time: 58-72 hours (PubMed=15650053).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: Mesenchymal stem cell of bone marrow; CL=CL_0002540.
CC   Breed/subspecies: (C57BL/6 x C3H) F2-op/op.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4398 ! OP9
SX   Sex unspecified
AG   Embryo
CA   Stromal cell line
DT   Created: 01-12-16; Last updated: 29-06-23; Version: 9
//
RX   Patent=US9121008;
RA   Tsai S.;
RT   "Development of natural killer cells and functional natural killer
RT   cell lines.";
RL   Patent number US9121008, 01-Sep-2015.
//
RX   PubMed=15650053; DOI=10.1182/blood-2004-11-4237;
RA   DeHart S.L., Heikens M.J., Tsai S.;
RT   "Jagged2 promotes the development of natural killer cells and the
RT   establishment of functional natural killer cell lines.";
RL   Blood 105:3521-3527(2005).
//